Form 4: Supernus Director Sells $161K in Stock

Supernus Pharmaceuticals Director Charles W. Newhall III executed a pre-planned sale of 3,588 shares of common stock for approximately $161,497.

Summary

• Charles W. Newhall III, a Director of Supernus Pharmaceuticals, Inc. (SUPN), sold 3,588 shares of the company's common stock.
• The transaction occurred on August 27, 2025, at a weighted average price of $45.01 per share.
• The shares were sold in multiple transactions with prices ranging from $45.00 to $45.04.
• This sale was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted on March 3, 2025.
• Following this transaction, Mr. Newhall directly beneficially owns 129,644 shares of Supernus Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be seen as negative, the pre-planned nature via a 10b5-1 plan mitigates concerns about opportunistic selling, suggesting it's for personal financial planning rather than a negative view on company prospects.

Positives

• The sale was executed under a pre-arranged Rule 10b5-1 trading plan, indicating it was not an opportunistic or reactive sale based on recent non-public information.

Negatives

• A director's sale of shares reduces their direct equity stake in the company, which can sometimes be perceived negatively by the market.

Future Outlook

No forward-looking statements or guidance were provided in this filing, as it is solely a report of an insider stock transaction.

Industry Context

This filing reports an individual insider transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may note the reduction in a director's direct ownership, though the pre-planned nature of the sale may temper any negative interpretations.

Key Dates

Recommendation

A single, pre-planned insider sale, particularly under a Rule 10b5-1 plan, is generally not a strong enough signal to warrant a change in investment recommendation. Such sales are often for personal financial management (e.g., diversification, liquidity) and do not necessarily reflect a change in the director's long-term outlook on the company's fundamentals or future performance. Investors should consider broader company performance, industry trends, and other financial metrics for a comprehensive investment decision.

Keywords

Supernus Pharmaceuticals, SUPN, Form 4, Insider Trading, Stock Sale, Director, Charles W. Newhall III, 10b5-1 Plan